AGTR1 AS A MARKER FOR BEVACIZUMAB COMBINATION THERAPIES
- 专利权人:
- 发明人:
- Juan De La Haba-Rodriguez,Pedro Sanchez-Rovira
- 申请号：
- US13911912
- 公开号：
- US20140030257A1
- 申请日:
- 2013.06.06
- 申请国别(地区):
- US
- 年份:
- 2014
- 代理人:
- 摘要：
- The present invention provides methods for assessing the responsiveness or sensitivity of a patient to bevacizumab, compositions comprising bevacizumab and methods of treating patients with bevacizumab.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- 베바시주맙 병용 치료를 위한 마커로서의 AGTR1
- Marker for determination of sensitivity to triplet combination anti-cancer agent
- Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
- COMPOSITION OF A FIRST NON-LABELED MONOCLONAL ANTIBODY BINDING TO A TUMOR ANTIGEN AND A NON-CROSS REACTIVE SECOND MONOCLONAL ANTIBODY LABELED WITH A NIR FLUORESCENCE LABEL
- Composition of a first non-labeled monoclonal antibody binding to a tumor antigen and a non-cross reactive second monoclonal antibody labeled with a NIR fluorescence label
